For the year ending 2025-12-31, VRCA had -$16,182K decrease in cash & cash equivalents over the period. -$17,627K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Total revenue | 35,577 |
| Total selling, general and administrative | 35,220 |
| Total research and development | 8,855 |
| Loss on disposal of assets | -246 |
| Cost of product revenue | 2,192 |
| Cost of license and collaboration revenue | 1,249 |
| Other segment items | 5,701 |
| Net loss | -17,886 |
| Stock-based compensation | 3,318 |
| Depreciation expense | 133 |
| Non-cash interest expense | 2,475 |
| Loss on disposal of fixed assets | -246 |
| Amortization of operating lease right-of-use asset | 296 |
| Amortization of finance lease right-of-use asset | 352 |
| Change in obligation for r&d funding liability | 754 |
| Non-cash r&d expense related to warrant vesting | 51 |
| Impairment of right-of-use asset | 0 |
| Loss on termination of financing lease | -1 |
| Loss on extinguishment of debt | -1,533 |
| Change in fair value of derivative liability | 2,648 |
| Prepaid expenses and other assets | 264 |
| Deferred revenue | 782 |
| Accounts payable | 176 |
| Accounts receivable | 5,212 |
| Collaboration receivable, billed and unbilled | 108 |
| Accrued expenses and other current liabilities | -1,311 |
| Operating lease liability | -315 |
| Net cash used in operating activities | -17,627 |
| Purchases of property and equipment | 0 |
| Sale of fixed assets | 0 |
| Net cash used in investing activities | 0 |
| Proceeds from exercise of stock options | 0 |
| Proceeds from issuance of debt, net of issuance costs | 0 |
| Proceeds from issuance of common stock, pre-funded warrants and warrants | 50,067 |
| Issuance costs for common stock, pre-funded warrants and warrants | 310 |
| Cash paid to settle debt | 35,030 |
| Repayment of debt | 12,789 |
| Debt amendment costs | 110 |
| Repayment of finance lease | 383 |
| Net cash provided by financing activities | 1,445 |
| Net decrease in cash and cash equivalents | -16,182 |
| Cash and cash equivalents at the beginning of the year | 46,329 |
| Cash and cash equivalents at the end of the year | 30,147 |
Verrica Pharmaceuticals Inc. (VRCA)
Verrica Pharmaceuticals Inc. (VRCA)